News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 639 results
September 2010
-
Media ReleaseNovartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progressionGilenya is the first approved oral treatment indicated for relapsing forms of MS in the US, a major advance for people with this diseaseGilenya showed superior efficacy by reducing relapses by 52% at…
-
Media ReleaseNovartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
August 2010
-
Media ReleaseNovartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure-- Tekamlo combines in a single-pill the only approved direct renin inhibitor, Tekturna, with the widely prescribed calcium channel blocker, amlodipine-- Data showed Tekamlo significantly reduced…
-
Media ReleaseNovartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
May 2010
-
Media ReleaseUS Affiliate of Novartis Strongly Disputes Claims of Past Discrimination in the US- The Novartis US affiliate, Novartis Pharmaceuticals Corporation (NPC), is committed to active and progressive policies and programs supporting the advancement of women in the sales force- NPC…
-
Media ReleaseUS Affiliate of Novartis Strongly Disputes Claims of Past Discrimination in the US
October 2009
-
Media ReleaseNovartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court- Alabama Supreme Court directs entry of final judgment in favor of NPC- Alabama Supreme Court ruling confirms State of Alabama's claims unfounded- NPC pleased by ruling, as the company reported true…
-
Media ReleaseNovartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
July 2009
-
Media ReleaseFDA Approves Tekturna HCT® as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent- Tekturna HCT combines the only approved direct renin inhibitor, Tekturna®, with widely used diuretic, hydrochlorothiazide, in a single pill- Data show combination of Tekturna and…
-
Media ReleaseFDA Approves Tekturna HCT® as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
June 2009
-
Media ReleaseVideo: New Biological Therapy Ilaris® Approved in US to Treat Children and Adults with CAPS, a Serious Life-Long Auto-Inflammatory Disease- Phase III data show rapid and sustained remission in more than 90% of Ilaris-treated patients with cryopyrin-associated periodic syndrome (CAPS) - Ilaris is the first approved treatment for…
-
Media ReleaseVideo: New Biological Therapy Ilaris® Approved in US to Treat Children and Adults with CAPS, a Serious Life-Long Auto-Inflammatory Disease
Pagination
- ‹ Previous page
- 1
- …
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- › Next page